Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Adam J LuginbuhlJennifer M JohnsonLarry A HarshyneAlban J LinnenbachSanket K ShuklaAngela AlnemriGaurav KumarDavid M CognettiJoseph M CurryNikita KotlovZoya AntyshevaSandrine DegryseKyle MannionMichael K GibsonJames NettervilleBrandee BrownRita AxelrodRalph ZinnerMadalina TulucStacey K MardekianBenjamin E LeibyAyako ShimadaMy G MahoneyUbaldo Martinez-OutschoornUlrich RodeckYoung J KimAndrew P SouthAthanassios ArgirisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Preoperative nivolumab ± tadalafil is safe in HNSCC and results in more than 50% of the patients having a pathologic treatment response of at least 20% after 4 weeks of treatment. Pretreatment specimens identified HPV status-dependent signatures that predicted response to immunotherapy while posttreatment specimens showed augmentation of the immune microenvironment with the addition of tadalafil.
Keyphrases
- locally advanced
- end stage renal disease
- lower urinary tract symptoms
- benign prostatic hyperplasia
- newly diagnosed
- ejection fraction
- rectal cancer
- stem cells
- genome wide
- peritoneal dialysis
- prognostic factors
- patients undergoing
- squamous cell carcinoma
- high grade
- radiation therapy
- dna methylation
- replacement therapy
- patient reported
- smoking cessation
- liver metastases
- preterm birth